Corcept Therapeutics

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. (öffnet in neuem Tab)

  Stock Titan · 01.10.2026

• Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027 (öffnet in neuem Tab)

  Investing.com · 29.09.2026

• Corcept Therapeutics stock carries a raised 2026 outlook (öffnet in neuem Tab)

  AD HOC NEWS · 29.09.2026

• Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each (öffnet in neuem Tab)

  Stock Titan · 28.09.2026

• Corcept Therapeutics’ oncology president sells $29,842 in stock (öffnet in neuem Tab)

  Investing.com · 28.09.2026

• Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com (öffnet in neuem Tab)

  Investing.com Canada · 28.09.2026

• Is Corcept Therapeutics (CORT) Undervalued After CHMP Backing For Relacorilant? (öffnet in neuem Tab)

  Simply Wall Street · 27.09.2026

• Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT) (öffnet in neuem Tab)

  Yahoo Finance · 25.09.2026

• Corcept Therapeutics Soars on Europe Cancer Drug Nod (öffnet in neuem Tab)

  tipranks.com · 24.09.2026

• CORT Looks 59.9% Overvalued on GF Value™ (öffnet in neuem Tab)

  GuruFocus · 23.09.2026

• Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires (öffnet in neuem Tab)

  citybiz.co · 23.09.2026

• Corcept Therapeutics Announces New Endocrinology Division President (öffnet in neuem Tab)

  tipranks.com · 23.09.2026

• Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant (öffnet in neuem Tab)

  TradingView · 23.09.2026

• Corcept names Justin Gunn to lead endocrinology division By Investing.com (öffnet in neuem Tab)

  Investing.com Canada · 23.09.2026

• Corcept Announces Planned Leadership Transition (öffnet in neuem Tab)

  Business Wire · 23.09.2026

• Corcept Stock Sinks Despite Drug Win Euphoria (öffnet in neuem Tab)

  tipranks.com · 23.09.2026

• Does EU Ovarian Cancer Backing Change The Bull Case For Corcept Therapeutics Stock? (öffnet in neuem Tab)

  Simply Wall Street · 23.09.2026

• Health Care Weekly: Corcept Seeks Dismissal of Off-Label Marketing Whistleblower Suit; Medicare ACCESS Program to Cover More Chronic Conditions; FDA Launches Accelerated Investigational Drug Review Program; Agencies Announce Fresh Steps to C (öffnet in neuem Tab)

  The Capitol Forum · 23.09.2026

• Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus (öffnet in neuem Tab)

  Yahoo Finance · 22.09.2026

• Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle (öffnet in neuem Tab)

  Yahoo Finance · 21.09.2026

• Corcept Therapeutics stock falls after Q2 2026 earnings jump and analyst focus on risk-reward (öffnet in neuem Tab)

  AD HOC NEWS · 20.09.2026

• Corcept's Lifyorli recommended in EU for platinum-resistant ovarian cancer (öffnet in neuem Tab)

  app.dealroom.co · 20.09.2026

• Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE) (öffnet in neuem Tab)

  The Globe and Mail · 19.09.2026

• Corcept Therapeutics president Vieira sells $29,842 of stock (öffnet in neuem Tab)

  Investing.com India · 19.09.2026

• Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval (öffnet in neuem Tab)

  Yahoo Finance · 18.09.2026

• Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week (öffnet in neuem Tab)

  Seeking Alpha · 18.09.2026

• Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) (öffnet in neuem Tab)

  Yahoo Finance · 18.09.2026

• Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years (öffnet in neuem Tab)

  Benzinga · 17.09.2026

• Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? (öffnet in neuem Tab)

  Yahoo Finance · 16.09.2026

• Corcept Grows to Mid-Cap on Institutional Support (öffnet in neuem Tab)

  Yahoo Finance · 16.09.2026